Nuwellis, Inc. (NUWE) Financial Ratio Screen
Track NUWE screening changes
Get an email when this stock's published screening status or underlying ratios change.
MSCI new-inclusion financial-ratio snapshot
NUWE financial screening at a glance
Calculation date: 2026-09-01. Financial period used: December 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.
Independent method comparison
What the available screens say
How MSCI, FTSE and S&P-style screens differThe request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.
Business activity evidence
Activity assessment in progress
The supplied classification (Medical Devices) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.
Revenue segments: SEC filing extraction found 1 dimensioned facts; 1 have passed extraction review. No activity conclusion is made. Open the SEC annual filing.
Reviewed counting basis: 1 non-overlapping leaves cover 100.00% of the filing revenue total — evidence basis reconciled. 0 included activities remain ambiguous. This is an assisted evidence review, not external Shariah approval.
View SEC-extracted business segments
- Fluid Overload — 100.0% of filing total · extraction accepted · activity: permissible · hierarchy: leaf · counting: included
Profile description reviewed: Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings
A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.
Published-ratio reproductions (not certifications)
The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| MSCI | 5.4% / 30% | 17.7% / 30% | 42.1% / 30% | N/A | INSUFFICIENT / NOT IMPLEMENTED* |
| S&P-style (provisional) | 0.0% / 33% | N/A | N/A | N/A | FINANCIAL SCREEN PASSED* |
| FTSE | 5.4% / 33% | 17.7% / 33% | 42.1% / 50% | N/A | INSUFFICIENT / NOT IMPLEMENTED* |
Financial Highlights
Profitability
| Gross Margin | 65.5% | |
| Operating Margin | -190.1% | |
| Net Margin | -217.2% | |
| Return on Equity (ROE) | -609.4% | |
| Return on Assets (ROA) | -112.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$11M |
| Free Cash Flow | -$11M |
| Total Debt | $328,000 |
| Debt-to-Equity | 9.9 |
| Current Ratio | 1.6 |
| Total Assets | $6M |
Price & Trading
| Last Close | $4.45 |
| 50-Day MA | $8.72 |
| 200-Day MA | $54.37 |
| Avg Volume | 2.3M |
| Beta | 0.3 |
|
52-Week Range
$1.61
| |
Financial data provenance and verification
The displayed fields were imported from yfinance on 2026-08-03 for the financial period December 2025. This is a secondary data feed and can differ from amended or newly filed statements.
- Issuer website — use its investor-relations filings to verify the figures.
- SEC EDGAR filing search — primary filing source for US issuers.
- Field mapping, formulas and limitations.
Historical market-cap evidence
36 monthly estimates are retained from
2023-08-31 to
2026-07-31. Each point combines a
month-end close from
Nasdaq public historical endpoint
with an SEC-reported share count. The
latest share evidence is dated
2026-05-11
(10-Q,
tag dei:EntityCommonStockSharesOutstanding,
accession 0001140361-26-021649).
Open SEC XBRL evidence.
Open Nasdaq price evidence.
When 36 completed months are available, these observations support
a provisional independent S&P-style leverage calculation.
This reconstruction is not official S&P index data, does not prove
index membership, and does not complete the separate activity-income
screen. DJIM remains unavailable.
Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.
About Nuwellis, Inc. (NUWE)
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Popular halal stock checks
Explore other frequently viewed automated stock screens and compare the available financial ratios.
Frequently Asked Questions
Is Nuwellis, Inc. (NUWE) halal to invest in?
The current automated result is More financial data is needed. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.
What is Nuwellis, Inc.'s debt ratio?
Nuwellis, Inc.'s debt ratio is 5.4% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.
What are Nuwellis, Inc.'s key financial metrics?
Nuwellis, Inc. has a market capitalization of USD 160,429 in its listing currency, trailing P/E ratio of 0.0, and revenue of $8M. The company maintains a gross margin of 65.5% and a net margin of -217.2%. Return on equity stands at -609.4%.
How often is the screening data updated?
Calculation date: 2026-09-01. Financial period: December 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.